Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or “the Company ...

JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

Novavax (NVAX) ended the recent trading session at $10, demonstrating a -1.19% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.92%.

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Novavax, Inc. and Encourages Investors to Contact the Firm Attorney Advertising--Bronstein, Gewirtz ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

GAITHERSBURG, Md., Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and ...

Novavax Inc. NVAX Novavax’s stock took a hit, dropping 19.44% to close at $10.15. The intraday high and low were $10.67 and $9.62, with a 52-week range of $3.53 to $23.86. The FDA has placed a ...